SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
Globe Newswire•29/10/2026•08:00 ET
0
Key Highlights
- ➤SCYNEXIS leadership to participate in Guggenheim Healthcare Innovation Conference November 9-11, 2026
- ➤Fireside chat scheduled November 9 from 2:30 p.m.-3:00 p.m. ET
- ➤One-on-one investor meetings scheduled for November 9-10, 2026
- ➤SCY-770 targets ADPKD and has received Orphan Drug designation
- ➤SCY-247 remains in clinical development for invasive fungal diseases
JERSEY CITY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that the SCYNEXIS senior leadership team will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference, taking place November 9-11, 2026, in Boston.
Fireside Chat Date: Monday, November 9, 2026 Time: 2:30 p.m.-3:00 p.m. ET
Get started
Create a free account to read the full story.